A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5
doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of
seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®)
and one out of seven will only receive inactive substances (placebo.)